EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial

Zhong Zheng, Huayin Wang, Huijuan Yang, Jie Tang, Xi Cheng, Meiqin Zhang, Yulan Ren, Xiaojun Chen, Xinzhu Ju, Liya Xu, Xiaohua Wu

BJOG: An International Journal of Obstetrics & Gynaecology · 2025

DOI: 10.1111/1471-0528.18178 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2025. Verfasst von Zhong Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shan…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Maintenance Chemotherapy, Ovarian Neoplasms. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Shanghai Science and Technology Committee, Shanghai Shenkang Hospital Development Center, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of adjuvant chemotherapy of three steps (ACTS) in patients newly diagnosed with advanced ovarian cancer.

Design

Randomised clinical trial.

Setting

The study was conducted at a single centre. Population Newly diagnosed patients with advanced ovarian cancer who showed a complete response to standard chemotherapy (paclitaxel plus carboplatin) were included in this study.

Methods

In this open‐label phase II trial, patients were randomised 1:1 to receive either ACTS therapy or no maintenance treatment. The ACTS group received step‐2 chemotherapy with cyclophosphamide and etoposide (six cycles) and step‐3 chemotherapy with cyclophosphamide and carboplatin (six cycles). Key endpoints were overall survival (OS), progression‐free survival (PFS) and adverse events. Main Outcome Measures The main outcome measures were OS, PFS and adverse events.

Results

Of the 130 enrolled patients, 65 were assigned to the ACTS group and 65 to the control group. The median OS in the ACTS group was 61.2 months, and patients in the ACTS group had a significantly longer PFS than those in the control group (22.2 vs. 9.73 months). The most common grade ≥ 3 adverse events were thrombocytopenia and neutropenia. No treatment‐related deaths occurred during the study period.

Conclusions

The Maintenance ACTS Regimen Improved PFS but Not OS and Showed a Tolerable Safety Profile in Patients Newly Diagnosed With Advanced Ovarian cancer. Trial Registration ClinicalTrials.org NCT02562365

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsMaintenance ChemotherapyOvarian NeoplasmsAdultAgedFemaleHumansMiddle AgedCarboplatinChemotherapy, AdjuvantCyclophosphamideEtoposidePaclitaxelProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

ACTS maintenance therapyadjuvant chemotherapy of three stepschemotherapy for ovarian cancerefficacyovarian cancersafety

Substanzen

CarboplatinCyclophosphamideEtoposidePaclitaxel

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Förderung

  • Shanghai Science and Technology Committee
  • Shanghai Shenkang Hospital Development Center
  • Shanghai Municipal Health Commission
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Municipal Hospital Development Center

Zitieren

APA

Zheng, Z., Wang, H., Yang, H., Tang, J., Cheng, X., Zhang, M., Ren, Y., Chen, X., Ju, X., Xu, L., & Wu, X. (2025). Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.18178

Vancouver

Zheng Z, Wang H, Yang H, Tang J, Cheng X, Zhang M, et al. Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2025. doi:10.1111/1471-0528.18178

BibTeX
@article{Zheng2025,
  author = {Zheng, Zhong and Wang, Huayin and Yang, Huijuan and Tang, Jie and Cheng, Xi and Zhang, Meiqin and Ren, Yulan and Chen, Xiaojun and Ju, Xinzhu and Xu, Liya and Wu, Xiaohua},
  title = {Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2025},
  doi = {10.1111/1471-0528.18178}
}
Kostenlos starten →